<DOC>
	<DOCNO>NCT02978040</DOCNO>
	<brief_summary>Primary percutaneous coronary intervention ( PCI ) main reperfusion therapy patient ST-elevation myocardial infarction ( STEMI ) . The optimal platelet inhibition time PCI fundamental , however , comparative speed action cangrelor oppose tirofiban chew integer load dose prasugrel unknown . The purpose trial ass inhibition platelet aggregation different regimen platelet inhibition ( tirofiban bolus+infusion , cangrelor bolus+infusion , prasugrel chew load dose , prasugrel integer load dose ) early phase primary PCI .</brief_summary>
	<brief_title>Randomized Comparison Cangrelor , Tirofiban Prasugrel Patients With STEMI Referred Primary PCI .</brief_title>
	<detailed_description>Primary percutaneous coronary intervention ( PCI ) main reperfusion therapy patient ST-elevation myocardial infarction ( STEMI ) . Ancillary pharmacological therapy include dual antiplatelet therapy aspirin inhibitor P2Y12 receptor , responsible adenosine diphosphate ( ADP ) -mediated platelet activation.Prasugrel ticagrelor recent efficient oral P2Y12 inhibitor available date . However , STEMI even prasugrel ticagrelor could significant delay onset action . Early in-ambulance administration increase inhibition P2Y12 receptor , however , benefit versus risk balance remain uncertain . Recently , small-scale independent study suggest chew crushed load dose ticagrelor prasugrel achieve pronounce platelet inhibition compare standard whole tablet soon drug administration . Yet , delay platelet inhibition remain considerable even chew crushed load dose new oral P2Y12 inhibitor suboptimal modulation platelet reactivity time primary intervention may persist . Tirofiban cangrelor intravenous drug rapid onset offset action compare oral agent . Both agent extensively test clinical trial include patient STEMI . However , comparative speed action cangrelor oppose tirofiban chew integer load dose prasugrel unknown . The propose investigation prospective , randomize , design STEMI patient undergo primary PCI randomize receive Cangrelor Tirofiban Prasugrel ( patient randomize receive chew integer tablet ) . Pharmacodynamic test perform several time point test investigator ' study hypothesis : 1 ) Cangrelor similar inhibitory effect Tirofiban ( non-inferiority Cangrelor compare Tirofiban ) ; 2 ) Compared Prasugrel , Cangrelor Tirofiban achieve prompt enhance platelet inhibitory effect ( superiority Tirofiban Cangrelor integer Prasugrel ) ; 3 ) Compared integer load dose Prasugrel , chew Prasugrel regimen achieve prompt enhance platelet inhibitory effect ( superiority chew Prasugrel integer Prasugrel ) . This study provide insight pharmacodynamic effect drug help clinician choose appropriate treatment avoid complication related inadequate platelet inhibition early phase patient STEMI undergo primary PCI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Age great 18 year old STsegment elevation myocardial infarction Referred primary PCI either within 12 h symptom onset 12 24 h onset evidence continue ischemia Unconsciousness Other condition make patient incapable receiving integer load dose prasugrel Any contraindication and/or know hypersensitivity allergy aspirin , prasugrel , intravenous unfractionated heparin , cangrelor , tirofiban Any contraindication primary PCI Administration glycoprotein IIb/IIIa inhibitor ( GPI ) P2Y12inhibitors cangrelor &lt; 7 day Chronic dialysis Recent ( &lt; 15 day ) current major bleeding Recent ( &lt; 15 day ) major surgery Administration fibrinolytics &lt; 30 day Current use indication oral anticoagulant Previous stroke transient ischemic attack ( TIA ) Inability follow procedure study ( language problem , psychological disorder , dementia ) comorbidities associate less 6 month survival ( active malignancy drug alcohol abuse , etc . ) Women pregnant breast feed potential become pregnant course study ( age &lt; 55 year last menstruation within last 12 month ) undergo tubal ligation , ovariectomy hysterectomy Participation another study investigational drug within 30 day precede present study Enrolment investigator , his/her family member , employee dependent person</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Antiplatelet therapy</keyword>
	<keyword>Cangrelor</keyword>
	<keyword>Tirofiban</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Acute Myocardial Infarction</keyword>
	<keyword>Primary Percutaneous Coronary Intervention</keyword>
	<keyword>Pharmacokinetic/Pharmacodynamic</keyword>
</DOC>